Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine.
Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine. Approximately 10% to 15% of prostate cancers and lymphomas may be particularly vulnerable to these treatments, and taking advantage of this genetic weakness could help save patient lives.
According to Anindya Dutta, MD, PhD, chairman of the Department of Biochemistry and Molecular Genetics at the School of Medicine, many cancers are not treated with radiotherapy or chemotherapy at the outset. Instead, someone with prostate cancer gets surgery or androgen deprivation first.
“But suppose you find the patient’s cancer belongs to this 10% group…those patients should really be treated with chemotherapy and radiotherapy right at the outset, because those cancer cells will be much more susceptible, while the normal cells around the cancer won’t be hurt at the doses needed,” Dutta said in a statement.
Dutta’s team discovered that a gene that plays an important role in repairing damaged DNA had a second, different gene overlapping it. The researchers found that when 1 gene is deleted, the other gene is absent as well, which leaves cells highly susceptible to treatments that damage the DNA inside cancer cells.
When these patients are treated with radiation and chemotherapy, the resulting DNA breaks in the cancecr cells are difficult to fix, therefore, causing the cancer cells to die.
“And now we discover that certain cancer cells—these 10% of prostate cancer and lymphomas—have this natural genetic vulnerability,” Dutta said. “They have lost the genes important for stitching the DNA back together, so they’re extremely susceptible to chemotherapy and radiotherapy.”
Using these findings, a blood test can be developed that determined which patients would benefit from being treated with chemotherapy and radiation. Decreasing the activity of repair genes while treating a patient with radiotherapy or chemotherapy will make the cancer more susceptible to treatment, Dutta added.
“The biochemical pathway we’ve unraveled for [one of the genes] gives us hope that we should be able to find small chemicals that could interrupt this activity,” he said.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More